Asahi Kasei Unifies Global Pharmaceutical Operations Under Asahi Kasei Therapeutics Brand
Asahi Kasei has announced plans to bring its pharmaceutical businesses in Japan, the United States, Sweden and Germany together under the Asahi Kasei Therapeutics brand, establishing a unified global management structure for its pharmaceutical operations. The integration will bring Asahi Kasei Therapeutics in Japan, Veloxis Pharmaceuticals in the United States, Calliditas Therapeutics in Sweden and recently acquired AiCuris Anti-infective Cures in Germany under a common organizational framework.
The move represents a significant step in Asahi Kasei’s strategy to expand its pharmaceutical business internationally and develop a global specialty pharmaceutical platform. The company is targeting pharmaceutical net sales of ¥300 billion by fiscal year 2030, with future growth expected to come from existing commercial products, pipeline programs, strategic acquisitions and additional in-licensing transactions.
By consolidating its pharmaceutical businesses under one global structure, Asahi Kasei aims to improve coordination across regions, strengthen resource allocation and create a more integrated approach to research, development, commercialization and business development.
Building a Global Specialty Pharmaceutical Business
Asahi Kasei has been expanding its pharmaceutical operations beyond its traditional base in Japan through a series of strategic investments and acquisitions. The company’s approach is focused on specialty therapeutic areas where significant unmet medical needs remain and where specialized scientific and commercial capabilities can support sustainable growth.
The company’s pharmaceutical strategy currently emphasizes areas including immunology, nephrology, transplantation and infectious diseases. These fields provide opportunities for Asahi Kasei to leverage specialized research capabilities while developing focused commercial franchises.
The unified Asahi Kasei Therapeutics structure is intended to bring together expertise from the company’s different pharmaceutical organizations and enable decisions to be made at a global level rather than separately by individual companies or geographic markets.
“Bringing our pharmaceutical businesses under a single global management structure will allow us to make resource allocation decisions across the business rather than by company or geography,” said Yoshikazu Aoki, Global President of Asahi Kasei Therapeutics.
According to Aoki, the new structure is also expected to strengthen the company’s ability to identify and pursue in-licensing opportunities. Such transactions are expected to play an important role in expanding Asahi Kasei’s pharmaceutical pipeline and supporting future growth.
The unified organization will operate around a shared mission, vision and set of values, with the goal of coordinating teams across different regions while continuing to develop new treatment options for patients.
Expansion Through Strategic Acquisitions
Asahi Kasei’s global pharmaceutical platform has been built through a series of acquisitions that have progressively expanded its geographic reach and therapeutic capabilities.
In 2020, Asahi Kasei acquired Veloxis Pharmaceuticals, establishing a stronger commercial presence in the United States with a focus on kidney transplantation. The acquisition provided Asahi Kasei with an established specialty pharmaceutical platform and a commercial product in the U.S. transplantation market.
The company expanded its kidney disease capabilities further in 2024 through the acquisition of Calliditas Therapeutics. The transaction strengthened Asahi Kasei’s commercial operations in the United States while also adding established operations and pharmaceutical development capabilities in Europe.
More recently, Asahi Kasei acquired AiCuris Anti-infective Cures in Germany in 2026. The transaction expanded the pharmaceutical portfolio into infectious diseases and added further development capabilities to the company’s European operations.
The integration of these businesses under Asahi Kasei Therapeutics creates a structure that connects the capabilities gained through these transactions with existing pharmaceutical operations in Japan.
Rather than operating the acquired businesses as separate organizations, the company intends to use the combined platform to coordinate strategic priorities and allocate resources across its global pharmaceutical portfolio.
Commercial Portfolio Provides Growth Foundation
The combined organization brings together several established products and development programs that provide a foundation for Asahi Kasei’s pharmaceutical growth strategy.
One of the key commercial products is ENVARSUS XR®, an extended-release formulation of tacrolimus used in kidney transplantation. Following Asahi Kasei’s acquisition of Veloxis in 2020, U.S. sales of ENVARSUS XR have recorded a compound annual growth rate in the 20% range, according to the company.
The product has provided with an established commercial platform in the U.S. transplant market and represents an important component of the company’s specialty pharmaceutical business.
Calliditas added another significant commercial asset through TARPEYO®, a delayed-release formulation of budesonide. The product is used in the treatment of IgA nephropathy, a kidney disease, and has contributed to the expansion of Asahi Kasei’s nephrology portfolio.
Asahi Kasei expects TARPEYO to continue outperforming the revenue projections that were established when the company acquired Calliditas.
The addition of AiCuris further broadens the portfolio through infectious disease products and pipeline assets. AiCuris contributes a royalty stream associated with Prevymis®, or letermovir, as well as development programs that could provide additional opportunities for future growth.
Together, these assets give Therapeutics a combination of commercial products, royalty-generating assets and pipeline opportunities across several specialty therapeutic areas.
Strengthening U.S. and European Operations
The integration also reflects the growing importance of Western markets to Asahi Kasei’s pharmaceutical strategy.
The acquisitions of Veloxis, Calliditas and AiCuris have expanded the company’s presence across the United States and Europe, providing commercial, clinical development and scientific capabilities outside Japan.
Stacy Wheeler, Chief Executive Officer of Therapeutics in the United States and Europe, said the four organizations bring together extensive scientific and operational experience.
“These four legacy companies bring together decades of scientific innovation, specialized expertise, and a shared commitment to patients,” Wheeler said.
According to Wheeler, combining the experience of these teams with Asahi Kasei’s scientific capabilities and established commercial foundation creates an opportunity to expand the existing portfolio, advance pipeline programs and identify additional opportunities in specialty therapeutic areas.
The unified structure could also support greater collaboration among teams working across different therapeutic areas and regions. By bringing commercial and development capabilities into a common organization, expects to create a platform capable of supporting both current products and future pipeline investments.
Increased Focus on In-Licensing
Business development and in-licensing are expected to be important elements of Asahi Kasei’s strategy as the company works toward its fiscal 2030 pharmaceutical revenue objective.
Under its medium-term management plan, plans to invest approximately ¥40 billion in in-licensing activities over a three-year period. The planned investment is intended to supplement continued spending on existing commercial products and internally developed pipeline assets.
In-licensing could allow Therapeutics to add differentiated products or development-stage assets without relying exclusively on internal research and development. The company can potentially use the capabilities of its global organization to evaluate opportunities across specialty therapeutic areas and geographic markets.
Aoki said that the unified structure would provide a stronger platform for pursuing these opportunities while enabling resource allocation decisions to be made across the broader pharmaceutical business.
The strategy also creates a framework through which future acquisitions could be integrated into the global organization rather than maintained as separate regional operations.
Working Toward ¥300 Billion in Pharmaceutical Sales
The consolidation of Asahi Kasei’s pharmaceutical businesses comes as the company works toward its goal of generating ¥300 billion in pharmaceutical revenue by fiscal year 2030.
The company expects this growth to be supported by several sources. Existing products, including ENVARSUS XR and TARPEYO, are expected to provide the foundation for continued commercial expansion. AiCuris’s royalty portfolio and development pipeline offer additional opportunities, while Asahi Kasei’s broader pipeline is expected to contribute to future growth.
Beyond the current portfolio, the company plans to pursue further mergers and acquisitions and in-licensing transactions to expand its specialty pharmaceutical business.
The unified structure may also allow Asahi Kasei to assess potential opportunities more efficiently by drawing on expertise from its Japanese, U.S. and European operations.
A More Integrated Global Pharmaceutical Platform
The transition to the Asahi Kasei Therapeutics brand marks a new organizational phase for the company’s pharmaceutical business. The integration brings together organizations that have developed expertise in transplantation, nephrology, immunology and infectious diseases, while creating a common management framework for global operations.
For Asahi Kasei, the strategy is designed to balance the strength of its existing commercial portfolio with continued investment in innovation and business development. The company intends to use its combined scientific, clinical and commercial capabilities to identify opportunities in specialty pharmaceutical markets where unmet medical needs remain.
The integration of Veloxis, Calliditas and AiCuris with Asahi Kasei’s existing pharmaceutical business also reflects the company’s broader internationalization strategy. The acquisitions have progressively expanded the company’s presence in major pharmaceutical markets and added specialized capabilities that can now be coordinated through a single global organization.
Asahi Kasei Therapeutics will therefore serve as the unified platform for the company’s pharmaceutical activities as it continues to develop its existing portfolio, advance pipeline programs and pursue additional opportunities.
The company’s long-term strategy will focus on strengthening specialty pharmaceutical franchises, expanding its global commercial reach and investing in new assets through in-licensing and M&A. Through these activities, Asahi Kasei aims to build toward its fiscal 2030 objective of ¥300 billion in pharmaceutical net sales while continuing to develop medicines addressing significant unmet medical needs.
For more information about Asahi Kasei Therapeutics, visit Asahi Kasei Therapeutics.
About Asahi Kasei
Asahi Kasei is a diversified global company that contributes to life and living for people around the world. Since its foundation in 1922, with businesses in ammonia and cellulose fiber, Asahi Kasei has consistently grown through proactive portfolio transformation to meet the evolving needs of every age. With 50,000 employees worldwide, the company contributes to sustainability by providing solutions to the world’s challenges across its three business sectors: Healthcare, Homes, and Material.